Zobrazeno 1 - 10
of 19
pro vyhledávání: '"Hirotomi Cho"'
Autor:
Hiroyuki Abe, Tsuyoshi Mori, Kaori Tomida, Hirotomi Cho, N Itoi, Yoshihiro Kubota, Yuki Kawai, Tohru Tani, Tomoko Umeda
Publikováno v:
Cancer Research. 72:P1-15
Background: Although taxanes have become a key chemotherapeutic drug in breast cancer treatment. Taxanes inhibit the growth of cancer cells by disrupting the functioning of their microtubules; however, the microtubules of nerve cells are also affecte
Autor:
Hajime Abe, Yoshihiro Kubota, Tohru Tani, Tsuyoshi Mori, Yuki Kawai, Tomoko Umeda, Hirotomi Cho
Publikováno v:
Breast Cancer. 21:202-207
TC (docetaxel 75 mg/m2 and cyclophosphamide 600 mg/m2 q3w) combination is used for neoadjuvant/adjuvant chemotherapy in primary breast cancer. The incidence of allergic reaction is reportedly more common in patients who receive docetaxel before cyclo
Autor:
Hajime Abe, Yuki Kawai, Yoshimasa Kurumi, Tsuyoshi Mori, Hirotomi Cho, Tohru Tani, Yoshihiro Kubota, Tomoko Umeda
Publikováno v:
International Journal of Clinical Oncology. 18:487-491
The tolerance and safety associated with the administration order of the anthracycline and taxane drugs have not been evaluated.Breast cancer patients with node-positive or high-risk patients with node-negative were eligible. The feasibility and toxi
Autor:
Tsuyoshi Mori, Tomoko Umeda, Yoshihiro Kubota, Hirotomi Cho, Hajime Abe, Tomoharu Shimizu, Makiko Tanaka, Yuki Kawai, Tohru Tani, Yoshimasa Kurumi
Publikováno v:
Surgery Today. 41:197-202
This study presents a new method that enables the detection of sentinel lymph nodes (SLN) with high sensitivity using indocyanine green (ICG) fluorescence imaging.This study enrolled 128 patients with clinically node-negative breast cancer. Fluoresce
Publikováno v:
Nihon Rinsho Geka Gakkai Zasshi (Journal of Japan Surgical Association). 72:2723-2729
症例は69歳,男性.数年前より,左鼠径ヘルニアの脱出と自己還納を繰り返していた.3日前にも同ヘルニア脱出を認め自己還納を行った.その後,上腹部痛,嘔気・嘔吐が出現し当院を
Autor:
Masayoshi Ohta, Kazuya Kataoka, Yoshihisa Suzuki, Mari Dezawa, Namiko Ishikawa, Hirotomi Cho, Chizuka Ide
Publikováno v:
Journal of Biomedical Materials Research Part A. :1118-1124
It is said that bone marrow stromal cells (BMSCs) are able to differentiate into different kinds of cells, including Schwann cells, under relevant conditions (Dezawa et al., Eur J Neurosci 2001;14:1771-1776). In the previous paper, we demonstrated th
Autor:
Mari Dezawa, Hiroshi Kanno, Mikio Hoshino, Hirotomi Cho, Naoya Matsumoto, Yutaka Itokazu, Nobuyoshi Tajima, Hitoshi Yamada, Hajime Sawada, Hiroto Ishikawa, Toshirou Mimura, Masaaki Kitada, Yoshihisa Suzuki, Chizuka Ide
Publikováno v:
Journal of Clinical Investigation. 113:1701-1710
Bone marrow stromal cells (MSCs) have the capability under specific conditions of differentiating into various cell types such as osteocytes, chondrocytes, and adipocytes. Here we demonstrate a highly efficient and specific induction of cells with ne
Autor:
Aya, Tokuda, Hajime, Abe, Yuki, Kawai, Tomoko, Umeda, Kaori, Tomida, Tsuyoshi, Mori, Hirotomi, Cho, Yoshihiro, Kubota, Tohru, Tani
Publikováno v:
Gan to kagaku ryoho. Cancerchemotherapy. 41(3)
Here we present a case of breast cancer in which cardiac dysfunction had previously been observed on trastuzumab(TRS) administration; the condition then improved but reoccurred on readministration of TRS. A 52-year-old woman received preoperative che
Autor:
Hajime, Abe, Tomoko, Umeda, Yuki, Kawai, Makiko, Tanaka, Tsuyoshi, Mori, Hirotomi, Cho, Yoshihiro, Kubota, Eiji, Mekata, Yoshimasa, Kurumi, Tohru, Tani
Publikováno v:
Gan to kagaku ryoho. Cancerchemotherapy. 37(10)
It has been thought that there is a possibility that infusion speed generally affects the manifested frequency of infusion reaction and its strength. The infusion prescription time of trastuzumab should be over 90 minutes according to the package ins
Autor:
Hajime, Abe, Tomoko, Umeda, Makiko, Tanaka, Yuki, Kawai, Tsuyoshi, Mori, Hirotomi, Cho, Yoshihiro, Kubota, Eiji, Mekata, Yoshimasa, Kurumi, Tohru, Tani
Publikováno v:
Gan to kagaku ryoho. Cancerchemotherapy. 37(8)
As adjuvant chemotherapy for breast cancer, the addition of taxane to regimens containing anthracycline has been shown to be effective. However, in Japan, it is not probability yet as for safety. We examined the feasibility of FEC 100 followed by DOC